1-2 of 2
Susan M. Clardy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy, Alex Uttard, Bingfan Du, Kalli C. Catcott, Kelly L. Lancaster, Elizabeth Ditty, Jack Sadowsky, Jeffrey Zurita, Naniye Malli, LiuLiang Qin, Stephen P. Bradley, Kenneth Avocetien, Tyler Carter, Dokyong Kim, Mark Nazzaro, Ling Xu, Thomas H. Pillow, Neelie T. Zacharias, Gail D. Lewis, Rebecca K. Rowntree, Radha Iyengar, David H. Lee, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 84–91.
https://doi.org/10.1158/1535-7163.MCT-23-0262
Published: 03 January 2024
View article titled, Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Open the PDF for Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios in another window
Includes: Supplementary data
Journal Articles

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 885–895.
https://doi.org/10.1158/1535-7163.MCT-20-0166
Published: 01 May 2021
View article titled, Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Open the PDF for Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect in another window
Includes: Supplementary data